1. Romania Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Biofarm SA

Biofarm SA

BBVB:BIO
1.37
RON
+0.01
(+0.74%)
0.08EPS
17.25P/E
1.35BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.11
0.13
0.15
0.15
0.17
0.19
0.2
0.22
0.24
0.28
0.28
0.29
0.32
0.3
Basic EPS, GAAP
0.02
0.03
0.03
0.03
0.04
0.04
0.05
0.06
0.06
0.07
0.08
0.08
0.1
0.08
Free Cash Flow per Basic Share
0.01
0.01
- -
0.02
0.02
0.03
0.05
0.01
0.05
- -
0.05
0.03
0.07
0.05
Dividend per Share
0.01
- -
0.01
0.02
0.02
0.02
0.01
0.03
0.02
0.02
0.03
0.03
0.03
0.07
Book Value per Share
0.16
0.17
0.18
0.2
0.22
0.23
0.26
0.3
0.34
0.39
0.44
0.49
0.56
0.4
Tangible Book Value per Share
0.16
0.17
0.18
0.2
0.22
0.23
0.26
0.3
0.34
0.39
0.44
0.48
0.55
0.4
Basic Weighted Avg Shares
1,095
985
985
986
985
985
985
985
985
985
985
985
985
985
Sales/Revenue/Turnover
118
129
149
152
170
184
195
216
239
277
280
287
319
294
Operating Margin (%)
22.9
40.55
21.32
23.59
26.06
25.73
31.21
29.44
28.82
28.52
27.57
27.29
33.49
25.96
Depreciation Expense
6
7
7
6
7
12
8
11
14
14
15
17
18
20
Net Income, GAAP
26
27
27
29
36
38
51
54
60
71
77
74
101
78
Effective Tax Rate (%)
12.14
2.51
14.25
16.83
15.58
18.55
18.55
16.32
13.22
12.32
8
11.98
12.48
11.76
Profit Margin (%)
21.74
20.6
18.23
19.38
21.16
20.86
26.05
25.07
25.25
25.6
27.48
25.94
31.51
26.59
Working Capital
100
97
92
93
98
95
114
132
155
188
217
253
343
188
LT Debt
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
1
1
1
Total Equity
176
169
182
197
216
225
257
292
333
380
434
478
548
395
Return on Invested Capital (%)
11.48
15.31
15.91
16.42
18.75
18.66
22.02
20.29
19.79
19.76
17.77
15.33
18.33
15.53
Return on Capital (%)
15.01
15.41
15.52
15.54
17.42
17.39
21.08
19.75
19.3
19.86
18.87
16.27
19.56
17.51
Return on Common Equity (%)
15.03
15.41
15.52
15.54
17.42
17.39
21.08
19.78
19.33
19.9
18.91
16.3
19.6
17.55

Capital Structure

RON

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
1
1
1
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
985
985
985
Market Capitalization
798
1,197
1,350

Working Capital

RON

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
430
464
396
Cash, Cash Equivalents & STI
170
232
208
Accounts Receivable, Net
147
144
86
Inventories
64
63
76
Total Current Liabilities
87
94
208
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

RON

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.7%
13.48%
14.65%
Free Cash Flow
-311.68%
-867.63%
92.7%
Net Income, GAAP
14.54%
13.84%
35.27%
Sales/Revenue/Turnover
8%
8.24%
11.36%
Total Cash Common Dividend
19.41%
1.8%
0.14%

Quarterly Revenue

RON

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
72
70
90
56
287
2025
95
68
100
56
319
2026
92
45
- -
- -
- -

Quarterly Earnings Per Share

RON

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.02
0.03
- -
0.08
2025
0.03
0.02
0.04
0.01
0.1
2026
0.03
-0.01
- -
- -
- -

Quarterly Dividends Per Share

RON

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.03
- -
0.03
2025
- -
- -
0.03
- -
0.03
2026
- -
0.04
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Catalin Constantin Vicol
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Bucharest Romania
IPO Date
Nov 19, 1996
Website
biofarm.ro
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Biofarm SA is a Romania-based pharmaceutical manufacturing company that develops, produces, and commercializes over-the-counter medications, prescription pharmaceuticals, dietary supplements, and medical devices. Founded in 1921 and headquartered in Bucharest, Romania, the company operates as a subsidiary of Poland-based Polpharma Group following a public takeover acquisition in 2026. Biofarm offers a diversified portfolio of over 100 products spanning more than 60 therapeutic areas; digestive and metabolic health products, including Triferment, Colebil, Anghirol, Carbocit, and Sennalax; respiratory and ear, nose, and throat remedies, including the Bioflu cold and flu line, Bixtonim decongestant sprays, and Antispasmin; pain relief and anti-inflammatory formulations under the Biofen brand; cardiovascular and circulatory support solutions, including Extravalerianic; central nervous system and sleep aids, including Nervocalmin; topical lotions and rubefacients under the Carmol brand; and nutritional supplements and multivitamins, including the Cavit and Bioland lines. The company manufactures solid, semi-solid, and liquid dosage forms, with specialized capabilities in soft gelatin capsules, compressed tablets, film-coated tablets, oral solutions, suspensions, and sprays. Biofarm distributes its products domestically to pharmacy chains, independent pharmacies, hospitals, and pharmaceutical wholesalers throughout Romania, while exporting to international markets including the Republic of Moldova, Hungary, Albania, Azerbaijan, Georgia, Iraq, and Kyrgyzstan. In recent corporate developments, Polpharma Group finalized the acquisition of Biofarm in mid-2026 in a transaction valued at approximately 270 million euros (1.36 billion RON), integrating the company into its regional pharmaceutical platform to broaden distribution across Central and Eastern Europe. Operationally, Biofarm has executed extensive capital investment and modernization programs at its Bucharest manufacturing complexes, including its Gura Badicului and Logofatul Tautu production and testing facilities, installing high-capacity tableting machinery, upgraded liquid preparation lines, certified Good Manufacturing Practice utility systems, and modernized research and development laboratories to scale manufacturing capacity up to 100 million units annually.